Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib maintenance/preemptive therapy in Ph+ ALL post-HSCT
NCT06658925Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Nov 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of olverembatinib in acute lymphoblastic leukemia (ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Relapse-Free Survival at 2 years. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
olverembatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06658925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06658925.